AMANDA WASHINGTON: Open Payments
NPI 1174257216 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$460 in 25 payments from 11 companies in 2025. Trend: 2023 $372 · 2024 $579 · 2025 $460
Food & beverage: $460
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $74 |
| AstraZeneca Pharmaceuticals LP | 4 | $69 |
| PFIZER INC. | 4 | $68 |
| Novo Nordisk Inc | 3 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| Astellas Pharma US Inc | 2 | $41 |
| Novartis Pharmaceuticals Corporation | 2 | $33 |
| Amgen Inc. | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $17 |
Products named: AIRSUPRA, NURTEC ODT, VRAYLAR, XIFAXAN, Veozah, LEQVIO, Wegovy, QULIPTA.
Industry payments across FL — which companies pay providers there.
